MCDERMOTT WILL & SCHULTE LLP for SURESCRIPTS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards. Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances (EPCS) in the Medicare Part D program and to encourage CMS to expand the use of EPCS beyond the Part D program. Efforts to support CMS rulemaking to ensure timely advancement of the NCPDP Formulary and Benefit Standard from Version 3.0 to Version 5.0 and to ensure timely adoption of a Real-Time Benefit Tool standard as soon as one is approved by NCPDP. Efforts to obtain clarity relating to the HIPAA Transactions Rule and Code Sets Rule to ensure that the eligibility transaction requirements do not apply to prior authorization requests for prescription drugs so that electronic prior authorization by non-Part D prescribers using the NPCPD SCRIPT Standard Version 2017071 is not impeded.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KAREN SEALANDER | — |
| SCOTT AARON WEINSTEIN | — |
Medicare/Medicaid MMM
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards. Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances (EPCS) in the Medicare Part D program and to encourage CMS to expand the use of EPCS beyond the Part D program. Efforts to support CMS rulemaking to ensure timely advancement of the NCPDP Formulary and Benefit Standard from Version 3.0 to Version 5.0 and to ensure timely adoption of a Real-Time Benefit Tool standard as soon as one is approved by NCPDP. Efforts to obtain clarity relating to the HIPAA Transactions Rule and Code Sets Rule to ensure that the eligibility transaction requirements do not apply to prior authorization requests for prescription drugs so that electronic prior authorization by non-Part D prescribers using the NPCPD SCRIPT Standard Version 2017071 is not impeded.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KAREN SEALANDER | — |
| SCOTT AARON WEINSTEIN | — |
Science/Technology SCI
Efforts to advance interoperability and to ensure that technological advances in electronic prescribing benefit patients, prescribers and others in the pharmacy services sector in a timely way, including improving the process for updating the SCRIPT electronic prescribing standard to allow for more expeditious adoption of updated electronic prescribing standards. Efforts to ensure timely implementation of the SUPPORT Act requirement for electronic prescribing of controlled substances (EPCS) in the Medicare Part D program and to encourage CMS to expand the use of EPCS beyond the Part D program. Efforts to support CMS rulemaking to ensure timely advancement of the NCPDP Formulary and Benefit Standard from Version 3.0 to Version 5.0 and to ensure timely adoption of a Real-Time Benefit Tool standard as soon as one is approved by NCPDP. Efforts to obtain clarity relating to the HIPAA Transactions Rule and Code Sets Rule to ensure that the eligibility transaction requirements do not apply to prior authorization requests for prescription drugs so that electronic prior authorization by non-Part D prescribers using the NPCPD SCRIPT Standard Version 2017071 is not impeded.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KAREN SEALANDER | — |
| SCOTT AARON WEINSTEIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.